一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Calderasib；Durvalumab；Placebo to MK-1084，当前状态为招募中。登记地点显示中国合肥、北京、厦门、南宁等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Calderasib；Durvalumab；Placebo to MK-1084 · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 2209) · 合肥
- Beijing Peking Union Medical College Hospital ( Site 2220) · 北京
- Zhongshan Hospital Affiliated to Xiamen University ( Site 2213) · 厦门
- The First Affiliated Hospital of Xiamen University. ( Site 2239) · 厦门
- Guangxi Medical University Cancer Hospital ( Site 2202) · 南宁
- Fourth Hospital of Hebei Medical University ( Site 2201) · 石家庄
- Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206) · 武汉
- Hubei Cancer Hospital ( Site 2203) · 武汉
- The Second Xiangya Hospital Of Central South University ( Site 2207) · 长沙
- Nanjing Drum Tower Hospital ( Site 2224) · 南京
- Shandong Cancer Hospital ( Site 2200) · 济南
- Zhongshan Hospital affiliated to Fudan University ( Site 2215) · 上海
- Fudan University Shanghai Cancer Center ( Site 2216) · 上海
- Shanxi Provincial Cancer Hospital ( Site 2227) · 太原
- Sichuan Cancer hospital. ( Site 2218) · 成都
- Taizhou Hospital of Zhejiang Province ( Site 2223) · 临海
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has a histological or cytological diagnosis of locally advanced, unresected Stage II (node-positive) to III non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology.
- * Has completed definitive platinum-based concurrent chemoradiotherapy (CCRT) prior to enrollment, without disease progression.
- * Has provided a tumor tissue sample for central laboratory testing of Kirsten rat sarcoma G12C (KRAS G12C) status, programmed cell death ligand 1 (PD-L1) status, and biomarker research.
- * Tumor tissue sample has a demonstrated presence of KRAS G12C mutation and an evaluable PD-L1 status result.
- * If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART).
- * If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy.
- * If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07554339；登记信息更新于 2026-09-14。